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Abstract Three patients belonging to two families
presented with a psychomotor-dysmorphism syndrome
including postnatal growth deficiency and major spon-
dylo-, epi-, and metaphyseal skeletal involvement. Other
features were muscular hypotrophy, fat excess, partial
growth hormone deficiency, and, in two of the three
patients, episodes of unexplained fever. Additional inves-
tigations showed mild to moderate increases of serum
transaminases (particularly of aspartate transaminase
(AST)), creatine kinase (CK), and lactate dehydrogenase
(LDH), as well as decreased coagulation factors VIII, IX,
XI, and protein C. Diagnostic work-up revealed a type 2
serum transferrin isoelectrofocusing (IEF) pattern and a
cathodal shift on apolipoprotein C-III IEF pointing to a
combined N- and O-glycosylation defect. Known glyco-
sylation disorders with similar N-glycan structures lack-
ing galactose and sialic acid were excluded. Through a
combination of homozygosity mapping and expression
profiling, a deep intronic homozygous mutation
(c.792 þ 182G>A) was found in TMEM165 (TPARL) in
the three patients. TMEM165 is a gene of unknown
function, possibly involved in Golgi proton/calcium trans-
port. Here we present a detailed clinical description of
the three patients with this mutation. The TMEM165
deficiency represents a novel type of CDG (TMEM165-
CDG). This disorder enlarges the group of CDG caused by
deficiencies in proteins that are not specifically involved in
glycosylation but that have functions in the organization
and homeostasis of the intracellular compartments and
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Congenital disorders of glycosylation (CDG) are genetic
defects of glycan synthesis and glycan attachment to
proteins and lipids. Their number is steadily growing with
some 50 CDG having been reported (Jaeken 2010, 2011;
Rafiq et al. 2011; Saigoh et al. 2011; Baasanjar et al. 2011;
Hennet 2012). Most of them are multisystem diseases, but
skeletal abnormalities are an important/predominant clinical
feature in only about 20 % of the known CDG. We present
three patients, including a brother and sister, with a novel
hypoglycosylation disorder characterized by a psychomotor
retardation-dysmorphism syndrome with postnatal growth
deficiency and major spondylo-, epi-, and metaphyseal
skeletal involvement. This paper describes the clinical and
laboratory findings in detail. The biochemical and molecu-




This boy is the first child of unrelated Ashkenazi parents
originating from Georgia. The second child is a healthy girl.
The third child, a girl, was similarly affected and will be
described in this paper as patient 2. Patient 1 was born at the
postmenstrual age of 40 weeks after a normal pregnancy.
Birth weight was 3,250 g (50th centile), length 50 cm (25th
centile), and head circumference 36 cm (50th centile). He
presented at the age of 5 weeks with feeding problems and
failure to thrive due to cow’s milk protein allergy. Growth
delay was noted within months. At 19 months of age, length
was 72 cm (3rd centile is 73 cm), weight 10.7 kg (10th
centile), and head circumference 48.5 cm (50th centile). Fat
excess, joint hyperlaxity, hypotonia, muscle weakness, and
hepatosplenomegaly were noted during the first years.
Psychomotor milestones were delayed: unsupported sitting
at 9 months, independent walking at 2 years, and first words
at 18 months. He was first seen in our hospital at the age of
11 years because of generalized epi-metaphyseal dysplasia
and joint destruction tentatively diagnosed as Desbuquois
syndrome. He presented with short stature (but normal head
growth), generalized adiposity, and muscular hypotrophy. He
had a waddling gait and was dysmorphic (midface hypopla-
sia, internal strabism of the right eye, moderately high arched
palate, small teeth, low-set and stiff auricles, pectus
carinatum, dorsolumbar kyphosis and severe sinistroconvex
scoliosis, short distal phalanges, genua vara, pedes plano-
valgi (Fig. 1)). Additional clinical features included rapidly
growing dense hair, long and dense eyelashes, delayed
dentition, a hoarse voice, joint hyperlaxity (particularly of the
interphalangeal joints) except for mild extension deficit of
elbows and knees and hip abduction of 45, joint “cracking”
when walking, and generalized hyporeflexia and hypotonia.
Laboratory investigations showed normal levels of
serum alkaline phosphatases, calcium, phosphate, osteocal-
cine, 1,25-hydroxyvitamin D, immunoglobulin G, blood
clotting factors II, V, X, XII, von Willebrand factor antigen,
von Willebrand factor Ristocetine cofactor, and antithrom-
bin, and increases of serum AST, ALT, CK, and LDH.
There was a mild to moderate decrease of cholinesterase,
and of clotting factors VIII, IX, XI, protein C, and protein S
(Table 1). At age 16 years, there was an onset of adrenarche
(circulating de-hydro-epi-androsterone-sulfate 52.4 mg/dL,
Fig. 1 Photograph of patient 1
Table 1 Abnormal results of serum parameters in the three patients
Patient 1 Patient 2 Patient 3 Normal
AST (U/L) 195–357 229–528 224–459 <32
ALT (U/L) 43–54 32–59 32–104 <31
CK (U/L) 1,376–1,915 297–2,546 319–918 <145
LDH (U/L) 540–703 749–608 587–967 240–480
Factor
VIII (%)
45 44 29 50–150
Factor
IX (%)
63 42 30 70–130
Factor
XI (%)
45 44 48 70–130
Protein
C (%)
66 48 67 70–150
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normal for age being 180–350 mg/dL) but not yet of
puberty (circulating luteinizing hormone 0.4 IU/L (normal
1.7–8.6 IU/L), follicle stimulating hormone 0.3 IU/L
(nl 1.2–7.7), total testosterone 25 ng/dL (nl 300–1,000),
free testosterone 0.27 ng/dL (nl 5–20), sex hormone
binding globuline 2.58 mg/dL (nl 0.7–1.6)).
Technical investigations: Imaging of the skeleton
showed osteoporosis and important epi- and metaphyseal
dysplasia with broad metaphyses, irregular epiphyses, and
thin bone cortex. The vertebrae were flattened and beaked
and the phalanges were broad (Fig. 2). On echocardiogra-
phy heart morphology and function were normal. Ophthal-
mological examination revealed a right convergent strabism
and “in fundo” temporal epithelial pigment alterations,
which were more pronounced in the left eye. MRI of
the brain showed some atrophy, enlarged ventricles,
periventricular and subcortical white matter abnormalities,
as well as relative hypoplasia of the anterior pituitary, and
absence of the normal hyperintensity of the posterior
pituitary. A skin biopsy was normal on histology as well
as on electronmicroscopy.
Tentative treatment with growth hormone (28 mg/kg/day)
in late prepuberty did normalize the circulating levels of
IGF-I (from <75 mg/L to >200 mg/L) and did reduce total-
body fat fraction from 28.5 % to 22.3 % within 1 year, but
failed to elicit a detectable increment of growth velocity
(possibly due to a concomitant aggravation of scoliosis) and
was thus halted after 2 years. At age 21, the young man has
a short stature (122.5 cm, Z-score 10) but a normal head
circumference (55 cm, between 10th and 25th centiles)
(Fig. 3).
Patient 2
This girl was the third child of unrelated Ashkenazi parents
from Georgia and the sibling of patient 1. Pregnancy and
delivery were uneventful. Hypotonia and hip dysplasia
were noted in early infancy.
She was admitted at age 5 months because of psycho-
motor delay, hypotonia, vomiting, and an infection-related
phase of respiratory insufficiency. The girl had ptosis of the
right upper eyelid, torticollis toward the left, external
strabism of the left eye, and had rather large lowly
implanted ears, a long filtrum, a high arched palate, a short
and broad neck, a broad thorax with increased nipple
distance, a sacral dimple, absent second-toe nails, hypo-
tonia, hyporeflexia, joint hyperlaxity, right hip dysplasia,
and hepatosplenomegaly (respectively, 2 and 3 cm below
the costal margin).
At 11 months she was readmitted because of recurrent,
unexplained fever up to 40C during 4 months. She was a
rather obese baby with weight 8.81 kg (between 25th and
50th centiles), length 68 cm (between 3rd and 10th
centiles), and head circumference 44.6 cm (25th centile).
She could sit unsupported for a few moments and roll over
from the side to the prone or supine position, but she was
not babbling. She had a large fontanel. The abdomen was
slightly enlarged with liver and spleen edge at 2 cm below
the costal margin. No cause for the recurrent fever was
identified.
At 14 months she was admitted with a pyelonephritis.
Her weight was then 8.5 kg (10th centile), and her length
and head circumference were virtually the same as at
a b c
d
Fig. 2 Radiological presentation of the skeleton of patient 1: (a) full spine at 20 years; (b) knee at 14 years 4 months; (c) elbow at 15 years
6 months; (d) hands at 15 years 6 months
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11 months (length Z-score 3.6, head circumference on
10th centile). One month later she died in an enterocolitis-
related episode of shock.
Laboratory investigations showed normal results for the
peripheral blood count, serum cholesterol (total, HDL-, and
LDL-), lactate, albumin, amino acids, thyroxine, thyroid
stimulating hormone, thyroxine-binding globuline, alkaline
phosphatase, osteocalcine, arylsulfatase A, PT, APTT,
clotting factors V, VII, X, XII, von Willebrand factor
antigen and von Willebrand factor Ristocetine cofactor,
protein S, platelet aggregation and platelet adhesion, as well
as the immunoglobulins A, G, M, and D. Urinary amino
acids, organic acids, and oligosaccharides were normal.
Abnormal results included increases of serum AST, ALT,
CK, LDH, and cerebrospinal fluid protein (566 mg/L;
normal 120–450). There was a slight decrease of serum
cholinesterase (6.3 kU/L; normal range 7–19) and of blood
clotting factors VIII, IX, XI, antithrombin, and protein C
(Table 1).
Technical investigations: Abdominal ultrasound exami-
nation was normal except for splenomegaly. Echocardiog-
raphy was normal. Radiological examination of the
skeleton showed generalized osteoporosis, discrete irregular
metaphyses of the long bones, discrete plathyspondyly,
broad iliac wings, horizontal acetabular roofs, and subluxa-
tion of the right femur. Ophthalmological investigation
showed macular epithelial pigment alterations. Electrophys-
iological examination revealed normal sensory nerve
conduction, whilst motor nerve conduction showed normal
velocities but decreased amplitudes. On electromyography
there were no active signs of denervation but sequelae
suggestive of past denervation. Muscular biopsy showed
normal histological and ultrastructural findings.
Patient 3
This boy was the fourth child of unrelated Ashkenazi
parents from Georgia. This family was not related to the
previously mentioned family. He was born after a normal
40 weeks pregnancy with birth weight of 3,360 g (25th
centile) and length of 49 cm (between 3rd and 10th
centiles). Hepatomegaly, a small open ductus Botalli and a
small patent foramen ovale, were noted shortly after birth.
The neonatal phase was complicated by blepharitis of the
right eye, feeding difficulties (attributed to cow’s milk
intolerance), diarrhea, and irritability with opisthotonus.
The boy presented craniofacial dysmorphism with relative
macrocephaly, tongue protrusion, anti-mongoloid slanting
of the eyes, a flat nose, and relatively large and posteriorly
rotated ears. At age 3 months, he was admitted because of
unexplained respiratory problems (restrictive lung pathol-
ogy) for which long-term invasive ventilation via tracheos-
tomy was started. Hypotonia, muscular weakness, body
adiposity, joint hyperlaxity (with cracking noise on mobili-
zation), and brisk tendon reflexes were noted. He had
regularly bouts of fever up to 38.5 C without evidence for
infection. At 14 months he developed epilepsy, responding
to levetiracetam. This could be be stopped at age 2 years
10/12. The mechanical ventilation could be stopped at age
3 and the tracheostomy was closed at age 4. At age 6 years,
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Fig. 3 Growth curves showing the evolution of length, weight, and head circumference in patients 1 and 3 (dotted lines); p3 is 3rd centile (full
line), p50 is 50th centile (full line)
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he does not follow normally with his eyes, does not grasp
for objects, and cannot sit unsupported; body length SDS is
approximately 7 but head circumference is normal
(49.9 cm, 25th centile) (Fig. 3). He has a distended,
tympanic abdomen with liver edge at 3 cm and spleen at
2 cm below the costal margin.
Laboratory investigations showed normal serum calcium,
phosphate, alkaline phosphatases, osteocalcine, arylsulfatase
A, prolactin, TSH, free T4, PT, aPTT, and cholinesterase.
Abnormal results included increases of serum AST, ALT,
CK, LDH, and decreases of serum haptoglobin (<0.2 g/L;
normal range 0.3–2), and of clotting factors VIII, IX, XI,
protein C, and protein S (Table 1).
Tentative treatment with growth hormone (30 mg/kg/day,
initiated at age 18 months) did normalize the circulating
levels of IGF-I (from 35 mg/L to 59 mg/L) and did reduce
total-body fat fraction from 27.4 % to 18.9 % within
5 months, but failed to elicit a detectable increment of
growth velocity or a detectable improvement of respiratory
status, and was thus halted.
Technical investigations: radiology of the skeleton at age
1 year revealed generalized osteopenia, a J-like sella
turcica, hypoplasia of the skull base, mild anterior beaking
of vertebrae D11, D12, L1, and L2, broad radial and ulnar
metaphyses, strongly underdeveloped carpal bones, plump
and broad phalanges, horizontal acetabula, very discrete
opacification of the right proximal femur epiphysis, no
ossification of the left proximal femur epiphysis, broad
proximal femur metaphyses, broad metaphyses and
strongly underdeveloped distal femoral and proximal tibial
epiphyses (Fig. 4). Echocardiography at 14 months was
normal except for a small pericardial effusion. Ophthalmo-
logical examination, electromyography (26 months), and
motor and sensory nerve conduction velocities were
normal. Brain MRI showed evidence for de- or dysmyeli-
nation and could not visualize the neural pituitary gland.
Methods
Isoelectrofocusing (IEF) of serum transferrin was
performed as described (Jaeken et al. 1984).
IEF of serum apolipoprotein C-III was performed as
described (Wopereis et al. 2003).
Transferrin N-glycan analysis by MALDI TOF MS
was performed as described in Sturiale et al. 2008 and
Papac et al. 1996 (data not shown).
Results
IEF of serum transferrin shows a type 2 pattern:
decrease of 6-, 5-, and 4-sialotransferrin and increase
of 3-, 2-, 1-, and 0-sialotransferrin (Fig. 5)
A                                              
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Fig. 4 Radiological presentation of the skeleton of patient 3: (a) knee
at the age of 1 year; (b) knee at 5 years 7 months; (c) lumbar spine at
1 year; (d) lumbar spine at 4 years; (e) foot at 22 m; (f) elbow at 3 years
10 months; (g) hand and wrist at 1 year; (h) hand and wrist at 3 years 6
months. See text for description
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IEF of apolipoprotein C-III shows a decrease of the
monosialo-apo C-III and an increase of the asialo-apo
C-III (Fig. 5)
Serum transferrin glycan analysis shows an increase of
the biantennary glycan lacking sialic acid, and an
abnormal biantennary glycan lacking sialic acid and
galactose. In addition there is an increased fucosylation
(data not shown)
Discussion
The described patients show a congenital disorder of
glycosylation with a type 2 serum transferrin pattern and
a cathodal shift of serum apoC-III pointing to a combined
N- and O-protein glycosylation defect. The known glyco-
sylation disorders with a type 2 serum transferrin IEF and
similar N-glycan structures (such as the COG-CDG) were
excluded by mutation analysis or linkage analysis.
Common clinical features include moderate psychomo-
tor retardation, feeding problems (in infancy), facial dys-
morphism with low-set ears, hypotonia, joint hyperlaxity,
hepatosplenomegaly, osteoporosis, and spondylo-, epi- and
metaphyseal dysplasia aggravating with age. After infancy
(patients 1 and 3), midface hypoplasia, muscular hypo-
trophy, fat excess, growth retardation, and partial growth
hormone deficiency completed this picture. An unusual
symptom in patients 2 and 3 (seen also in some COG-CDG
patients; Zeevaert et al. 2008) was recurrent fever without
evidence for infection. Features only present in patient 3
(family 2) were respiratory problems due to unexplained
restrictive lung pathology and transient epilepsy. It remains
uncertain whether these features are secondary to the CDG.
The main biochemical findings in all three patients were
an increase of serum AST (moderate), ALT (very mild), CK
(moderate), and LDH (mild), as well as a decrease of
coagulation factors VIII, IX, XI, and protein C. Ophthal-
mological examination in patients 1 and 2 showed macular
epithelial pigment alterations, and was normal in patient 3.
Common findings on brain MRI in patients 1 and 3 were
white matter abnormalities and absent visualization of the
neural pituitary gland.
Skeletal manifestations are an important/predominant
part of the phenotype in only about 20 % of the known
CDG: EXT1/EXT2-CDG (Jennes et al. 2009), B4GALT7
(Seidler et al. 2006), B3GAT3-CDG (Baasanjar et al. 2011),
GALNT3-CDG (Chefetz and Sprecher 2009), SLC35D1-
CDG (Hiraoka et al. 2007), LFNG-CDG (Sparrow et al.
2006), PIGV-CDG (Horn et al. 2011), autosomal recessive
cerebrocostomandibular like syndrome due to COG1-CDG
(Zeevaert et al. 2009), and ATP6V0A2-CDG (Guillard
et al. 2009). The spectrum of these skeletal manifestations
is very broad which can be explained by the fact that
glycosylation is an important posttranslational modification
of numerous proteins, including extracellular matrix












Fig. 5 Serum transferrin IEF and ApoC-III IEF in the three patients compared to a control. Sialo fractions (0 to 6 and 0 to 2, respectively) are
indicated on the left. C is control; P1 is patient 1; P2 is patient 2, P3 is patient 3
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proteins and proteins involved in bone metabolism, for
example, collagen I (Coman et al. 2007) and FGFR-3
(Winterpacht et al. 2000). The function of these proteins
can be affected by a changed or absent glycosylation site.
For example, a mutation affecting a putative glycosylation
site of FGFR-3 leads to hypochondroplasia. Other hypoth-
eses about the pathophysiology of bone abnormalities in
CDG include lysosomal dysfunction (Garel et al. 1998) and
polymorphisms in alternative pathways (Coman et al.
2008).
Thus, the bone anomalies in the three patients are
unprecedented among CDG patients. Clinically, their
skeletal phenotype can be classified in group 13 (among
40 groups) of the classification of genetic skeletal disorders
(revision 2010), namely, the spondylo-epi-(meta)-physeal
dysplasias (Warman et al. 2011).
Eventually, the molecular defect in these patients was
identified through a combination of homozygosity mapping
and expression profiling. The three patients are homozy-
gous for a deep intronic splice mutation in TMEM165
(TPARL) c.792 + 182G>A (Foulquier et al. 2012).
This mutation was not identified in 100 Jewish control
alleles.
This disorder enlarges the group of CDG that results
from deficiencies in proteins that are not specifically
involved in glycosylation but that have functions in the
organization and homeostasis of the intracellular compart-
ments and the secretory pathway. Other examples of these
are the COG-CDG (Foulquier 2009), ATP6V0A2-CDG
(Guillard et al. 2009), and SEC23B-CDG (Bianchi et al.
2009; Schwarz et al. 2009). We propose to call this CDG
subgroup “CDG plus”.
Take Home Message
Bone dysplasia is the main clinical feature of three patients
with a novel congenital disorder of glycosylation due to a
mutation in TMEM165.
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